ClinicalTrials.gg
WithdrawnNCT07152223Updated May 28, 2026

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

An interventional study of CAR-T in Connective Tissue Diseases, sponsored by Guangzhou Bio-gene Technology Co., Ltd. Withdrawn at 1 site in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-28.

Sponsored by Guangzhou Bio-gene Technology Co., Ltd · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Due to corporate strategic adjustment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
1 Year to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Connective Tissue Diseases with a site in China — 13 open to participants now, 18 under way, 7 of them phase 3. Connective Tissue Diseases · China.

Enrollment
22nd of 22
0 · median 224
Started
2025
with 1 other
No phase
Only one
of the 27
Registered
25th of 27
by date

Among the 27 studies in Connective Tissue Diseases with a site in China, this one is the 22nd largest by enrollment of the 22 interventional ones that give a count, is one of 2 that started in 2025, is the only one with no phase, and was the 25th registered.

Connective Tissue Diseases

192 studies on the registry are indexed under Connective Tissue Diseases; 56 are open to participants now.

Browse Connective Tissue Diseases studies →

Open to participants now

13 of the 27 studies in Connective Tissue Diseases with a site in China are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 43 Connective Tissue Diseases studies recruiting now, 30 (70%) set no upper age limit and 7 (16%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.

This study: 1 Year to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Connective Tissue Diseases with a site in China, or all of them as a file.
02

Study summary

This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.

03

Conditions studied

  • Connective Tissue Diseases

Keywords

  • Connective Tissue Diseases
04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Good compliance: The patient or their guardian understands and voluntarily signs the form, and it is expected that all documents, procedures, follow-up examinations and treatments stipulated in the study can be completed.
  2. Previously diagnosed with one of the following diseases and meeting the corresponding latest international classification/diagnostic criteria :

    1. Systemic lupus erythematosus (SLE);
    2. Rheumatoid arthritis (RA);
    3. Systemic scleroderma (SSc) ;
    4. Sjogren's Syndrome (SS);
    5. Polymyositis/dermatomyositis (PM/DM);
    6. Mixed connective tissue disease (MCTD).
  3. Researchers determine that the disease is in an active stage;
  4. At least one autoantibody is positive in the serum or plasma during the screening period;
  5. Insufficient response, intolerance or recurrence to at least one standard treatment;
  6. The pregnancy test of the female subjects was negative, and the subjects agreed to take effective measures throughout the trial period.
  7. The patient's major tissues and organs are functioning well.

Exclusion criteria

Exclusion Criteria:

  1. Intracranial hypertension or confusion;
  2. Symptomatic heart failure or severe arrhythmia;
  3. Respiratory failure;
  4. Accompanied by other types of malignant tumors;
  5. Diffuse vascular coagulation;
  6. Serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value;
  7. Sepsis or other difficult-to-control infections;
  8. Uncontrollable diabetes;
  9. Severe mental disorder;
  10. Cranial magnetic resonance imaging (MRI) examination revealed obvious lesions in the intracranial cavity.
  11. WHO physical status classification ≥ level 3;
  12. Organ transplant recipients;
  13. Pregnant and lactating women;
  14. +,,,EBV,CMV.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CAR-T

    The dosage range of 1.0 × 10\^6/kg (± 20%) to 3.0 × 10\^6/kg (± 20%) of CAR-T cells, administered intravenously.

    Biological: CAR-T

Interventions

  • BiologicalCAR-T

    Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.

06

What researchers measure

Primary outcomes

  1. Evaluation of Safety

    Count the Incidence of adverse events

    Time frame: Up to 2 years after CAR-T infusion

Secondary outcomes

  1. Effectiveness evaluation

    The response rate of the responder index of systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), systemic sclerosis (scleroderma SSc), Sjogren's Syndrome, polymyositis/dermatomyositis, and mixed connective tissue disease (MCTD), as well as the changes in scores compared with the baseline value

    Time frame: Up to 2 years after CAR-T infusion

  2. Pharmacokinetic parameters

    The highest concentration of CAR-T cell expansion in peripheral blood after administration.

    Time frame: Up to 2 years after CAR-T infusion

  3. Pharmacodynamic parameters

    The peak values of CAR-T-related cytokines, which include at least IL-6 and IFN-γ.

    Time frame: Up to 2 years after CAR-T infusion

07

Study locations

1 site
  • Dongguan Taixin Hospital
    Dongguan, Guangdong 523125, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in Mar 2026, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2025
First posted
Sep 3, 2025
StartActual
Aug 7, 2025
Primary completionActual
Mar 2, 2026
CompletionActual
Mar 2, 2026
Last update
May 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07152223
Lead sponsor
Guangzhou Bio-gene Technology Co., Ltd
Responsible party
Sponsor
First posted
Sep 3, 2025
Start date
Aug 7, 2025
Primary completion
Mar 2, 2026
Completion
Mar 2, 2026
Last update
May 28, 2026

Study contacts

Yuelin He, Ph.D. degree
principal investigator · Dongguan Taixin Hospital
Lan He, Ph.D. degree
principal investigator · Dongguan Taixin Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion